EUVIMED · CrossrefZeitschrift
European Heart Journal - Cardiovascular Pharmacotherapy
ISSN 2055-6837 · Oxford University Press (OUP)
Neueste Artikel
Impact of beta-blockers on quality of life in patients with myocardial infarction without heart failure: A prespecified substudy of the DANBLOCK trial
PharmaPlain: SOUL trial looking at the effect of oral semaglutide on cardiovascular outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease
Authors’ reply to: ‘Stent-free is not risk-free: risk-defined DAPT after DCB-only PCI in ACS’
Reply to Erre et al: translating cardio-rheumatology into practice: a multi-level pilot network
Eplerenone vs. spironolactone in heart failure: long-term cardiorenal and mortality outcomes in a registry-based cohort
Comparative biomarker efficacy of cholesteryl ester transfer protein inhibitors: a network meta-analysis
Translating cardiorheumatology into practice: a multilevel pilot network
Coated or chewable aspirin and a hybrid air pollution mitigation strategy in patients with atherosclerotic disease: rationale and design of the COATED-AIR randomized trial
Vagal activity-related events and glucagon-like peptide-1 receptor agonists
Switching to angiotensin receptor–neprilysin inhibitor and reduced risk of new-onset atrial fibrillation in heart failure with reduced ejection fraction: a nationwide propensity score–matched study
Rewriting heart health: epigenetic drugs in cardiovascular medicine
Antiemetic-associated QT prolongation: a clinical review and risk-stratified prescribing framework for long QT syndrome
From digital reminders to artificial intelligence–enabled understanding: can personalized treatment predictions improve therapeutic adherence?
Can ARNI prevent atrial fibrillation in heart failure with reduced ejection fraction? Real-world evidence meets the randomized benchmark
Advancing and implementing cardiovascular drug therapy
When randomization is not enough: divergent β-blocker trials and the illusion of universal causality
Urate-lowering therapy in cardiovascular pharmacotherapy: from Mendelian randomization data to cardio–renal–metabolic risk modulation
Semaglutide for primary prevention of major adverse cardiac and cerebrovascular events in patients with type 2 diabetes and comorbid rheumatoid arthritis: a target-trial emulation
Why cardio-rheumatology?
Initiation of eplerenone vs. spironolactone and all-cause mortality in HFrEF: linked database study
Impact of single vs. dual local anaesthetic regimen on the efficacy and safety of percutaneous stellate ganglion block for electrical storm: new insights from the STAR study
Heart failure and tricuspid regurgitation: the role of SGLT2 inhibitors in improving outcomes
Correction to: Cardiovascular pharmacotherapy in 2025
Effect of beta blockers in acute and chronic coronary syndromes without reduced ejection fraction: a landmark analysis from the REBOOT trial
Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials
Post-operative atrial fibrillation and stroke after non-cardiac surgery: a systematic review and meta-analysis
Anti-inflammatory pharmacotherapy in patients with cardiovascular disease
ODYSSEY-HCM trial (mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy)
Long-term effectiveness of ACE inhibitors or angiotensin receptor blockers in myocardial infarction with preserved left ventricular ejection fraction
Impact of left ventricular ejection fraction on the effect of beta-blocker therapy on 1-year mortality in acute coronary syndrome patients
EUVIMED